Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMC1WHR)

Drug Name
[3H]QNB Drug Info
Synonyms
3-Quinuclidinyl benzilate; 6581/6/2; 3-Chinuclidylbenzilate; 3-Quinuclidyl benzilate; 3-quinuclidinylbenzilate; 3-Quinuclidinol benzilate; Ro 2-3308; CHEMBL12980; Benzilic acid, 3-quinuclidinyl ester; (+/-)-QNB; NSC 173698; QNB; EA 2277; CS 4030; BZ; 1-Azabicyclo(222)octan-3-ol, benzilate; Buzz; Agent BZ; 1-azabicyclo[222]octan-3-yl 2-hydroxy-2,2-diphenylacetate; BZ [anticholinergic]; 4478-53-9; NSC170423; Benzilic acid, 3-quinuclidinyl ester, (+-)-; 3-quinuclidinyl-benzilate; [3H]quinuclidinylbenzilate; Benzeneacetic; [3H]quinuclidinylbenzilate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
23056
CAS Number
CAS 6581-06-2
TTD Drug ID
DMC1WHR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Muscarinic acetylcholine receptor (CHRM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetylcholine DMDF79Z Cataract 9B10 Approved [5]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [6]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [7]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [8]
Clidinium DMUMQZ0 Abdominal stomach pain DD91.4 Approved [9]
Oxybutynin hydrochloride DMF2KLU Urinary incontinence MF50.2 Approved [10]
Incruse Ellipta DM32GSJ Chronic obstructive pulmonary disease CA22 Approved [11]
Revefenacin DMMP5SI Chronic obstructive pulmonary disease CA22 Approved [12]
Scopolamine DMOM8AL Addictive disorder 6C50-6C5Z Approved [13]
Isopropamide iodide DMQYV60 Allergic rhinitis CA08.0 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Muscarinic acetylcholine receptor M3 (CHRM3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolterodine DMSHPW8 Overactive bladder GC50.0 Approved [15]
ACECLIDINE DMOLNCZ Glaucoma/ocular hypertension 9C61 Approved [16]
Tiotropium DMFDC0Q Chronic obstructive pulmonary disease CA22 Approved [17]
Ipratropium DMFQ320 Obstructive lung disease CA22.Z Approved [18]
Darifenacin DMWXLYZ Overactive bladder GC50.0 Approved [19]
Methacholine Chloride DMGS4QH Asthma CA23 Approved [20]
SMT-D002 DM1I93C Seborrhea ED91.2 Approved [21]
Solifenacin DMG592Q Overactive bladder GC50.0 Approved [22]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [23]
Cevimeline DMWSMND Sjogren syndrome 4A43.20 Approved [24]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [25]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [26]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [27]
Panobinostat DM58WKG Chronic graft versus host disease Approved [28]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [29]
Testosterone DM7HUNW Hot flushes GA30 Approved [30]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [30]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [31]
Acetylcholine DMDF79Z Cataract 9B10 Approved [32]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [32]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Affected By Muscarinic acetylcholine receptor M2 (CHRM2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [33]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [33]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [34]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [27]
Acetylcholine DMDF79Z Cataract 9B10 Approved [35]
Omadacycline DMR2J95 Acute bacterial skin infection 1C41 Approved [36]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [37]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [25]
Bardoxolone methyl DMODA2X Mixed connective tissue disease 4A43.3 Phase 3 [38]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [39]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Muscarinic acetylcholine receptor M4 (CHRM4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ALCURONIUM DM2U4XQ Anaesthesia 9A78.6 Approved [40]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Acetylcholine DMDF79Z Cataract 9B10 Approved [35]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [40]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [42]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [43]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [25]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [25]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [39]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Muscarinic acetylcholine receptor M5 (CHRM5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [45]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [41]
Acetylcholine DMDF79Z Cataract 9B10 Approved [46]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [33]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [33]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [39]
[3H]dimethyl-W84 DMBWAIE Discovery agent N.A. Investigative [33]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Affected By Muscarinic acetylcholine receptor M1 (CHRM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pirenzepine DMP6M1N Peptic ulcer DA61 Approved [47]
Gabapentin DM6T924 Complex partial seizure 8A68.0 Approved [48]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [49]
Acetylcholine DMDF79Z Cataract 9B10 Approved [50]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [32]
Clozapine DMFC71L Schizophrenia 6A20 Approved [51]
Olanzapine DMPFN6Y Bipolar depression Approved [52]
Gallamine Triethiodide DMPO0MS Stabilize muscle contraction FB3Z Approved [53]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [50]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [25]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor (CHRM) TTOXS3C NOUNIPROTAC Antagonist [2]
Muscarinic acetylcholine receptor M3 (CHRM3) TTQ13Z5 ACM3_HUMAN Antagonist [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Muscarinic acetylcholine receptor M1 (CHRM1) OTKW3E6B ACM1_HUMAN Protein Interaction/Cellular Processes [4]
Muscarinic acetylcholine receptor M2 (CHRM2) OTUMZ2WR ACM2_HUMAN Protein Interaction/Cellular Processes [4]
Muscarinic acetylcholine receptor M3 (CHRM3) OTKSD095 ACM3_HUMAN Protein Interaction/Cellular Processes [4]
Muscarinic acetylcholine receptor M4 (CHRM4) OTF0F0FF ACM4_HUMAN Protein Interaction/Cellular Processes [4]
Muscarinic acetylcholine receptor M5 (CHRM5) OTNQRQGG ACM5_HUMAN Protein Interaction/Cellular Processes [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3260).
2 Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. Brain Res. 2001 Oct 5;915(1):70-8.
3 Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9.
4 A snake venom inhibitor to muscarinic acetylcholine receptor (mAChR): isolation and interaction with cloned human mAChR. Arch Biochem Biophys. 2000 May 15;377(2):290-5. doi: 10.1006/abbi.2000.1784.
5 Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66.
6 Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70.
7 Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84.
8 Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35.
9 Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7.
10 Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66.
11 Clinical pipeline report, company report or official report of GlaxoSmithKline.
12 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
13 The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63.
14 Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7.
15 Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53.
16 Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7.
17 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
18 Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69.
19 M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5.
20 Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62.
21 Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64.
22 Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6.
23 Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94.
24 Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123.
25 Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
26 Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway. Toxicol In Vitro. 2010 Oct;24(7):1953-61. doi: 10.1016/j.tiv.2010.08.005. Epub 2010 Aug 12.
27 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
28 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
29 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
30 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
31 Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
32 Assessment of false transmitters as treatments for nerve agent poisoning. Toxicol Lett. 2020 Mar 15;321:21-31. doi: 10.1016/j.toxlet.2019.12.010. Epub 2019 Dec 9.
33 Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol. 2006 Jul;70(1):181-93. doi: 10.1124/mol.106.023481. Epub 2006 Apr 26.
34 Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
35 Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci. 1999;64(6-7):519-26. doi: 10.1016/s0024-3205(98)00596-7.
36 In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5247-53. doi: 10.1128/AAC.00320-16. Print 2016 Sep.
37 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
38 Characterization of the potent, selective Nrf2 activator, 3-(pyridin-3-ylsulfonyl)-5-(trifluoromethyl)-2H-chromen-2-one, in cellular and in vivo models of pulmonary oxidative stress. J Pharmacol Exp Ther. 2017 Oct;363(1):114-125.
39 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
40 Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Mol Pharmacol. 2006 Aug;70(2):736-46. doi: 10.1124/mol.106.024711. Epub 2006 May 18.
41 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
42 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
43 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
44 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
45 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
46 Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
47 Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J Med Chem. 2004 Aug 12;47(17):4300-15. doi: 10.1021/jm040800a.
48 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
49 Evaluation of first generation synthetic cannabinoids on binding at non-cannabinoid receptors and in a battery of in?vivo assays in mice. Neuropharmacology. 2016 Nov;110(Pt A):143-153. doi: 10.1016/j.neuropharm.2016.07.016. Epub 2016 Jul 20.
50 Regional differences in functional receptor distribution and calcium mobilization in the intact human lens. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2355-63.
51 Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport. 2002 May 7;13(6):831-5. doi: 10.1097/00001756-200205070-00019.
52 No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
53 Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207.